The Effect of Deprenyl and Isatin Administration to Mice on the Proteomic Profile of Liver Isatin-Binding Proteins

[1]  A. Kopylov,et al.  The Effect of Neurotoxin MPTP and Neuroprotector Isatin on the Profile of Ubiquitinated Brain Mitochondrial Proteins , 2018, Cells.

[2]  A. Ivanov,et al.  Isatin, an endogenous nonpeptide biofactor: A review of its molecular targets, mechanisms of actions, and their biomedical implications , 2018, BioFactors.

[3]  A. Ivanov,et al.  [Study specificity of isatin interactions with P450 cytochromes]. , 2018, Biomeditsinskaia khimiia.

[4]  O. El-Kabbani,et al.  Human carbonyl reductase 1 participating in intestinal first‐pass drug metabolism is inhibited by fatty acids and acyl‐CoAs , 2017, Biochemical pharmacology.

[5]  D. Mochly‐Rosen,et al.  Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) Protein-Protein Interaction Inhibitor Reveals a Non-catalytic Role for GAPDH Oligomerization in Cell Death* , 2016, The Journal of Biological Chemistry.

[6]  A. Sawa,et al.  The diverse functions of GAPDH: views from different subcellular compartments. , 2011, Cellular signalling.

[7]  Jun O. Liu,et al.  Carbonyl reductase 1 as a novel target of (−)‐epigallocatechin gallate against hepatocellular carcinoma , 2010, Hepatology.

[8]  A. Ivanov,et al.  Isatin‐binding proteins of rat and mouse brain: Proteomic identification and optical biosensor validation , 2010, Proteomics.

[9]  A. Kopylov,et al.  Isatin binding proteins in rat brain: In situ imaging, quantitative characterization of specific [3H]isatin binding, and proteomic profiling , 2009, Journal of neuroscience research.

[10]  N. Xiong,et al.  Involvement of glyceraldehyde-3-phosphate dehydrogenase in rotenone-induced cell apoptosis: Relevance to protein misfolding and aggregation , 2009, Brain Research.

[11]  Keith F. Tipton,et al.  The therapeutic potential of monoamine oxidase inhibitors , 2006, Nature Reviews Neuroscience.

[12]  V. Glover,et al.  Isatin: Role in stress and anxiety , 2005, Stress.

[13]  W. Tatton,et al.  Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B , 2003, Journal of Neural Transmission.

[14]  D. Chuang,et al.  Overexpression and nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase in a transgenic mouse model of Huntington’s disease , 2003, Molecular and Cellular Neuroscience.

[15]  A. Boulton,et al.  Aliphatic propargylamines as symptomatic and neuroprotective treatments for neurodegenerative diseases. , 2002, Neurotoxicology and teratology.

[16]  M. Anttila,et al.  Selegiline Metabolism and Cytochrome P450 Enzymes:In vitro Study in Human Liver Microsomes† , 2000 .

[17]  P. Fürst,et al.  Glyceraldehyde-3-phosphate Dehydrogenase, the Putative Target of the Antiapoptotic Compounds CGP 3466 andR-(−)-Deprenyl* , 1998, The Journal of Biological Chemistry.

[18]  A. Medvedev,et al.  Does isatin interact with rat brain monoamine oxidases in vivo? , 1997, Neuroscience Letters.

[19]  A. Clow,et al.  Isatin: a link between natriuretic peptides and monoamines? , 1996, Biochemical pharmacology.

[20]  T. Yoshida,et al.  Hepatic and extrahepatic metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor, of amphetamines in rats: sex and strain differences. , 1987, Xenobiotica; the fate of foreign compounds in biological systems.